Abstract
Shiga toxin-producing Escherichia coli (STEC), especially of serotype O157:H7, cause a zoonotic food or waterborne enteric illness that is often associated with large epidemic outbreaks as well as the hemolytic uremic syndrome (HUS), the leading cause of acute renal failure in children. After ingestion, STEC colonize enterocytes of the large bowel with a characteristic attaching and effacing pathology, which is mediated by components of a type III secretion apparatus encoded by the LEE pathogenicity island. Shiga toxins are translocated from the bowel to the circularoty system and transported by leukocytes to capillary endothelial cells in renal glomeruli and other organs. After binding to the receptor globotriaosylceramide on target cells, the toxin is internalized by receptor-mediated endocytosis and interacts with the subcellular machinery to inhibit protein synthesis. This leads to pathophysiological changes that result in HUS. Specific therapeutic or preventive strategies are presently not available. The recent sequencing of genomes of two epidemic E. coli O157 strains has revealed novel pathogenicity islands which will likely provide new insights into the virulence of these bacteria.
Similar content being viewed by others
References
Konowalchuk, J., Speirs, J.I., Stavric, S. (1977) Vero response to a cytotoxin of Escherichia coli. Inect. Immun. 18, 775–779.
Griffin, P.M. (1995) Escherichia coli O157:H7 and other enterohemorrhagic Escherichia coli. In: Blaser, M.J., Smith, P.D., Ravdin, J.I., et al., (eds.) Infections of the Gastrointestinal Tract. New York: Raven Press, Ltd, pp. 739–761.
Karmali, M.A., Steele, B.T., Petric, M., and Lim, C. (1983) Sporadic cases of hemolytic uremic syndrome associated with fecal cytotoxin and cytotoxin-producing Escherichia coli. Lancet I, 619–620.
Karmali, M.A., Petric, M., Lim, C., et al. (1985) The association between hemolytic uremic syndrome and infection by Verotoxin-producing Escherichia coli. J. Infect. Dis. 151, 775–782.
Nataro, J.P., Kaper, J.B. (1998) Diarrheagenic Escherichia coli. Clin.Microbiol.Rev. 11, 142–201.
Riley, L.W., Remis, R.S., Helgerson, S.D., et al. (1983) Hemorrhagic colitis associated with a rare Escherichia coli serotype. New Engl.J.Med. 308, 681–685.
Ahmed, S. and Donaghy, M. (1998) An outbreak of Escherichia coli O157:H7 in Central Scotland. In: Kaper, J.B. and O’Brien, A.D., (eds.) Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli strains. Washington, D.C., ASM Press; pp. 59–65.
CCDR. (2000) Waterborne outbreak of gastroenteritis associated with a contaminated municipal water supply, Walkerton, Ontario, May–June 2000. Can. Commun. Dis. Rep. 26, 170–173.
Karmali, M.A. (1989) Infection by Verocytotoxin-producing Escherichia coli. Clin.Microbiol.Rev. 2, 15–38.
Michino, H., Araki, K., Minami, S., et al. (1998) Recent outbreaks of infection caused by Escherichia coli O157:H7 in Japan. In: Kaper, J.B. and O’Brien, A.D., (eds.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. Washington, D.C., ASM Press, pp. 73–81.
Fitzpatrick, M.M., Shah, V., Trompeter, R.S., et al. (1991) Long term renal outcome of childhood haemolytic uraemic syndrome. Brit.Med.J. 303, 489–492.
Loirat, C., Sonsino, E., Moreno, A.V., et al. Hemolytic uremic syndrome: An analysis of the natural history and prognostic features. Acta Pediatr Scand 73, 505–514.
Siegler, R.L., Milligan, M.K., Burningham, T.H., et al. (1991) Long-term outcome and prognostic indicators in the hemolytic uremic syndrome. J.Pediatr. 118, 195–200.
Trompeter, R.S., Schwartz, R., Chantler, C., et al. (1983) Haemolytic uraemic syndrome: An analysis of prognostic features. Arch Dis Child 58, 101–105.
Advisory Committee on the Microbiological Safety of Food. (1995) Report on verocytotoxin-producing Escherichia coli. (1995) Her Majesty’s Stationary Office, London.
USDA:APHIS:VS. Escherichia coli O157:H7 issues and ramifications. 1994. Centers for Epidemiology and Animal Health, 555 South Howes, Fort Collins, Colorado, 80521.
World Health Organization. (1999) Zoonotic non-O157 Shiga toxin-producing Escherichia coli (STEC). Report of a WHO Scientific Working Group Meeting, Berlin, Germany, 22–23 June, 1998. WHO/CSR/APH/98.8. World Health Organization, pp. 1–30.
Lopez, E.L., Contrini, M.M., and Rosa, M.F. (1998) Epidemiology of shiga toxin-producing Escherichia coli in South America. In: Kaper, J.B and O’Brien, A.D. (eds). Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli strains. ASM Press, Washington, D.C, pp.30–37.
Gerber A, Karch H, Allerberger F, et al. (2002) Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: A prospective study. J.Infect.Dis. 186,493–500.
Tozzi, A.E., Caprioli, A., Minelli, F., et al. (2003) Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988–2000. Emerg.Infect.Dis. 9, 106–108.
Banatvala, N., Griffin, P.M., Greene, K.D et al. The United States National Prospective Hemolytic Uremic Syndrome Study: Microbiologic, serologic, clinical, and epidemiologic findings.
Centers for Disease Control and Prevention (1993). Update: Multistate outbreak of Escherichia coli O157:H7 infections from hamburgers—western United States, 1992–1993. J.Amer.Med.Assoc. 269, 2194–2196.
Griffin, P.M. (1998) Epidemiology of shiga toxin-producing Escherichia coli infections in humans in the United States. In: Kaper, J.B. and O’Brien, A.D. (eds.). Escherichia coli O157:H7 and other shiga toxin-producing E. coli strains. ASM Press, Washington, D.C, pp. 15–22.
Carter, A.O., Borczyk, A.A., Carlson, J.A.K. et al. (1987) A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N.Engl.J.Med. 317, 1496–1500.
Kibel, M.A. and Barnard, P.J. (1968) The hemolytic uremic syndrome: A survey in Southern Africa. S.Afr.Med.J. 42, 692–698.
Jernigan, S.M. and Waldo, F.B. (1994) Racial incidence of hemolytic uremic syndrome. Pediatr.Nephrol. 8 545–547.
Gianantonio, C., Vitacco, M., Mendilaharzu, F., et al. (1964) The hemolytic-uremic syndrome. J.Pediatr. 64, 478–491.
Gianantonio, C., Vitacco, M., Mendilaharzu, F., et al. (1973) The hemolytic uremic syndrome. Nephron 11, 174–192.
Tarr, P.I., Fouser, L.S., Stapleton, A.E., et al. (1996) Hemolytic-uremic syndrome in a six-year old girl after a urinary tract infection with shiga-toxin-producing Escherichia coli O103:H2. N.Engl.J.Med. 335, 635–660.
McLaine, P.N., Orrbine, E., Rowe, P.C. (1992) Childhood Hemolytic Uremic Syndrome in Canada: A multicenter study. In: Kaplan, B.S. (ed.). Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Marcel Dekker Inc., New York, pp. 61–69.
Upadhyaya, K., Barwick, K., Fishaut, M., et al. (1980). The importance of nonrenal involvement in hemolytic uremic syndrome. Pediatrics 65, 115–120.
Frankel, G., Phillips, A.D., Rosenshine, I., et al. (1998) Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol. Microbiol. 30, 911–921.
Goosney, D.L., DeVinney, R., Finlay, B.B. (2001) Recruitment of cytoskeletal and signaling proteins to enteropathogenic and enterohemorrhagic Escherichia coli pedestals. Infect.Immun. 69, 3315–3322.
Mellies, J.L., Elliott, S.J., Sperandio, V., et al. The Per regulon of enteropathogenic Escherichia coli: Identification of a regulatory cascade and a novel transcriptional activator, the locus of enterocyte effacement (LEE)-encoded regulator (Ler). Mol.Microbiol. 33, 296–306.
Sperandio, V., Mellies, J.L., Nguyen, W., et al. (1999) Quorum sensing controls expression of the type III secretion gene transcription and protein secretion in enterohemorrhagic and enteropathogenic Escherichia coli. Proc.Natl.Acad.Sci.USA 96, 15,196–15,201.
Friedrich, A.W., Bielaszewska, M., Zhang, W.L., et al. (2002) Escherichia coli harboring shiga toxin 2 gene variants: frequency and association with clinical symptoms. J.Infect.Dis. 185, 74–84.
O’Brien, A.D., Tesh, V.L., Donohue-Rolfe, A., et al. (1992) Shiga toxin: Biochemistry, genetics, mode of Action. and role in pathogenesis. Curr.Topics Microbiol. Immunol. 180, 65–94.
Lingwood, C.A., Law, H., Richardson, S.E., et al. (1987) Glycolipid binding of natural and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem. 262, 8834–8839.
Lingwood, C.A., Mylvaganam, M., Arab, S., Set al. (1998) Shiga toxin (verotoxin) binding to its receptor glycolipid. In: Kaper, J.B. and O’Brien, A.D. (eds.). Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. ASM Press, Washington, D.C. pp. 129–139.
te Loo, D.M., Hinsbergh, V.W., Heuvel, L.P., and Monnens, L.A. (2001) Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J. Am. Soc. Nephrol. 12, 800–806.
Fong, J.S.C., de Chadarevian, J.P., Kaplan, B. (1982) Hemolytic uremic syndrome. Current concepts and management. Pediatr. Clin. North Amer. 29, 835–856.
Richardson, S.E., Karmali, M.A., Becker, L.E., and Smith CR. (1988) The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli Infections. Hum. Pathol. 19, 1102–1108.
Vitsky, B.H., Suzuki, Y., Strauss, L., and Churg, J. (1969) The hemolytic uremic syndrome: A study of renal pathologic alternations. Am. J. Pathol. 57, 627.
Obrig, T. (1998) Interaction of shiga toxins with endothelial cells. In: Kaper, J.B. and O’Brien, A.D., (eds.). Escherichia coli O157:H7 and other shiga toxin-producing E. coli strains. ASM Press, Washington, D.C, pp. 303–311.
te Loo, D.M., Monnens, L.A., van den Heuvel, L.P., et al. (2001) Detection of apoptosis in kidney biopsies of patients with d+ hemolytic ure mic syndrome. Pediatr. Res. 49, 413–416.
Monnens, L., Savage, C.O., Taylor, C.M. (1998) Pathophysiology of hemolytic-uremic syndrome. In: Kaper, J.B. and O’Brien, A.D. (eds.). Escherichia coli O157:H7 and other shiga toxin-producing E. coli strains. ASM Press, Washington, D.C, pp. 287–292.
Taylor, C.M. and Monnens, L.A. (1998) Advances in haemolytic uraemic syndrome. Arch. Dis. Child 78, 190–193.
van Setten PA, Monnens, L.A., Verstraten, R.G., et al. (1996) Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 88, 174–183.
Kar, N.C.A.J., Monnens, L.A.H., Karmali, M.A., and Hinsbergh, V.W.M.. (1992) Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosyl ceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 80, 2755–2764.
Perna, N.T., Plunkett, G. III., Burland, V., et al. (2001) Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature 409,529–533.
Hayashi, T., Makino, K., Ohnishi, M., et al. (2001) Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res. 8, 11–22.
Karmali, M. A., Mascarenhas, M., Shen, S., et al. (2003) Association of genomic O island 122 of Escherichia coli EDL 933 with verocytotoxin-producing Escherichia coli seropathotypes that are linked to epidemic and/or serious disease. J. Clin. Microbiol. 41, 4930–4940.
Neill, M.A. (1998) Treatment of disease due to shiga toxin-producing Escherichia coli: Infectious disease management. In: Kaper, J.B. and O’Brien, A.D. (eds.). Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. ASM Press, Washington, D.C, pp. 357–363.
Takeda, T., Yoshino, K., Uchida, H., et al. (1998) Early use of fosfomycin for shiga toxin-producing Escherichia coli O157 infection reduces the risk of hemolytic-uremic syndrome. In: Kaper, J.B. and O’Brien AD, (eds.). Escherichia coli O157:H7 and other shiga toxin-producing E. coli strains. ASM Press, Washington, D.C, pp. 385–387.
Wong, C.S., Jelacic, S., Habeeb, R.L., et al. (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342, 1930–1936.
Levine, M.M. (1998) Immunoprophylaxis of shiga toxin-producing Escherichia coli infection and disease: strengths and weaknesses of various strategies. In: Kaper, J.B. and O’Brien, A.D., (eds.). Escherichia coli O157:H7 and other shiga toxin-producing E. coli strains. ASM Press, Washington, D.C, pp. 405–408.
Armstrong, G.D., McLaine, P.N., and Rowe, P.C. (1998) Clinical trials of synsorb Pk in preventing hemolytic uremic syndrome. In: Kaper, J.B. and O’Brien, A.D., (eds.). Escherichia col O157:H7 and other shiga toxin-producing E. coli strains. ASM Press, Washington, D.C., pp. 374–384.
Kitov, P.I., Sadowska, J.M., Mulvey, G., et al. (2000) Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403, 669–672.
Gyles, C.L. (1998) Vaccines and shiga toxin-producing Escherichia coli in animals. In: Kaper, J.B. and O’Brien, A.D. (eds.). Escherichia coli O157:H7 and other shiga toxin-producing E. coli strains. ASM Press, Washington, D.C., pp. 434–444.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Karmali, M.A. Infection by shiga toxin-producing Escherichia coli . Mol Biotechnol 26, 117–122 (2004). https://doi.org/10.1385/MB:26:2:117
Issue Date:
DOI: https://doi.org/10.1385/MB:26:2:117